An ad hoc planning committee will plan and conduct a public workshop that will examine the impact of and investment in the use of genetic and genomic data in drug development. The workshop will feature presentations and discussions from an array of stakeholders which may include leaders from academia, industry and governmental organizations. The goal of the workshop will be to discuss how genomic and genetic data have been and will be used in the drug development process to improve aspects such as target identification, clinical trial design, pharmacogenomics approaches, biomarker development and understanding disease biology. The workshop will also investigate the economic drivers, incentives, and models that use genomics in drug development. The planning committee will develop the workshop agenda, select and invite speakers and discussants, and moderate the discussions. An individually-authored summary of the workshop will be prepared by a designated rapporteur in accordance with institutional policy and procedures.